Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

Adaptation and validation of the self-report version of the scale for measuring quality of life in people with acquired brain injury (CAVIDACE).

Aza A, Verdugo MÁ, Orgaz MB, Fernández M, Amor AM.

Qual Life Res. 2019 Dec 18. doi: 10.1007/s11136-019-02386-4. [Epub ahead of print]

PMID:
31853880
2.

Measuring support needs in children with motor disability: Validity and utility of the Supports Intensity Scale (SIS-C).

Aguayo V, Arias VB, Verdugo MÁ, Amor AM.

Res Dev Disabil. 2019 Dec;95:103509. doi: 10.1016/j.ridd.2019.103509. Epub 2019 Oct 30.

PMID:
31675653
3.

Predictive factors of quality of life in acquired brain injury.

Verdugo MA, Fernández M, Gómez LE, Amor AM, Aza A.

Int J Clin Health Psychol. 2019 Sep;19(3):189-197. doi: 10.1016/j.ijchp.2019.06.004. Epub 2019 Aug 11.

4.

Assessing support needs in children with intellectual disability and motor impairments: measurement invariance and group differences.

Aguayo V, Verdugo MA, Arias VB, Guillen VM, Amor AM.

J Intellect Disabil Res. 2019 Dec;63(12):1413-1427. doi: 10.1111/jir.12683. Epub 2019 Sep 5.

PMID:
31486142
5.

Ancient cattle genomics, origins, and rapid turnover in the Fertile Crescent.

Verdugo MP, Mullin VE, Scheu A, Mattiangeli V, Daly KG, Maisano Delser P, Hare AJ, Burger J, Collins MJ, Kehati R, Hesse P, Fulton D, Sauer EW, Mohaseb FA, Davoudi H, Khazaeli R, Lhuillier J, Rapin C, Ebrahimi S, Khasanov M, Vahidi SMF, MacHugh DE, Ertuğrul O, Koukouli-Chrysanthaki C, Sampson A, Kazantzis G, Kontopoulos I, Bulatovic J, Stojanović I, Mikdad A, Benecke N, Linstädter J, Sablin M, Bendrey R, Gourichon L, Arbuckle BS, Mashkour M, Orton D, Horwitz LK, Teasdale MD, Bradley DG.

Science. 2019 Jul 12;365(6449):173-176. doi: 10.1126/science.aav1002.

6.

Examining measurement invariance and differences across groups in the support needs of children with and without intellectual disability.

Verdugo MA, Amor AM, Arias VB, Guillén VM, Fernández M, Arias B.

J Appl Res Intellect Disabil. 2019 Nov;32(6):1535-1548. doi: 10.1111/jar.12649. Epub 2019 Jul 5.

PMID:
31273870
7.

Ultrasound-Guided Hydraulic Release Associated With Corticosteroids in Radial Tunnel Syndrome: Description of Technique and Preliminary Clinical Results.

García N, Rosales J, Greene C, Droppelmann G, Verdugo MA.

J Ultrasound Med. 2020 Jan;39(1):165-168. doi: 10.1002/jum.15085. Epub 2019 Jul 3.

PMID:
31268176
8.

Lens cholesterol biosynthesis inhibition: A common mechanism of cataract formation in laboratory animals by pharmaceutical products.

Aleo MD, Doshna CM, Baltrukonis D, Fortner JH, Drupa CA, Navetta KA, Fritz CA, Potter DM, Verdugo ME, Beierschmitt WP.

J Appl Toxicol. 2019 Sep;39(9):1348-1361. doi: 10.1002/jat.3822. Epub 2019 Jun 24.

PMID:
31231834
9.

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables.

Roberts AW, Ma S, Kipps TJ, Coutre SE, Davids MS, Eichhorst B, Hallek M, Byrd JC, Humphrey K, Zhou L, Chyla B, Nielsen J, Potluri J, Kim SY, Verdugo M, Stilgenbauer S, Wierda WG, Seymour JF.

Blood. 2019 Jul 11;134(2):111-122. doi: 10.1182/blood.2018882555. Epub 2019 Apr 25.

10.

Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy.

Mato AR, Wierda WG, Davids MS, Cheson BD, Coutre SE, Choi M, Furman RR, Heffner L, Barr PM, Eradat H, Ford SM, Zhou L, Verdugo M, Humerickhouse RA, Potluri J, Byrd JC.

Haematologica. 2019 Nov;104(11):2258-2264. doi: 10.3324/haematol.2018.207068. Epub 2019 Mar 28.

11.

Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia.

Flinn IW, Gribben JG, Dyer MJS, Wierda W, Maris MB, Furman RR, Hillmen P, Rogers KA, Iyer SP, Quillet-Mary A, Ysebaert L, Walter HS, Verdugo M, Klein C, Huang H, Jiang Y, Lozanski G, Pignataro DS, Humphrey K, Mobasher M, Kipps TJ.

Blood. 2019 Jun 27;133(26):2765-2775. doi: 10.1182/blood-2019-01-896290. Epub 2019 Mar 12.

12.

Isolated posterior cruciate ligament aplasia: a case report.

García N, Debandi A, Delgado G, Rosales J, Verdugo M.

Skeletal Radiol. 2019 Sep;48(9):1439-1442. doi: 10.1007/s00256-019-3161-3. Epub 2019 Jan 28.

PMID:
30687879
13.

Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study.

Kater AP, Seymour JF, Hillmen P, Eichhorst B, Langerak AW, Owen C, Verdugo M, Wu J, Punnoose EA, Jiang Y, Wang J, Boyer M, Humphrey K, Mobasher M, Kipps TJ.

J Clin Oncol. 2019 Feb 1;37(4):269-277. doi: 10.1200/JCO.18.01580. Epub 2018 Dec 3.

14.

Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor.

Wierda WG, Byrd JC, Davids MS, Furman RR, Cheson BD, Barr PM, Eradat H, Heffner L, Zhou L, Verdugo M, Potluri J, Choi M.

Br J Haematol. 2019 Jun;185(5):961-966. doi: 10.1111/bjh.15666. Epub 2018 Nov 27. No abstract available.

15.

A new scale for measuring quality of life in acquired brain injury.

Fernández M, Gómez LE, Arias VB, Aguayo V, Amor AM, Andelic N, Verdugo MA.

Qual Life Res. 2019 Mar;28(3):801-814. doi: 10.1007/s11136-018-2047-5. Epub 2018 Nov 17.

PMID:
30448910
16.

Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study.

de Vos S, Swinnen LJ, Wang D, Reid E, Fowler N, Cordero J, Dunbar M, Enschede SH, Nolan C, Petrich AM, Ross JA, Salem AH, Verdugo M, Agarwal S, Zhou L, Kozloff M, Nastoupil LJ, Flowers CR.

Ann Oncol. 2018 Sep 1;29(9):1932-1938. doi: 10.1093/annonc/mdy256.

17.

Ancient goat genomes reveal mosaic domestication in the Fertile Crescent.

Daly KG, Maisano Delser P, Mullin VE, Scheu A, Mattiangeli V, Teasdale MD, Hare AJ, Burger J, Verdugo MP, Collins MJ, Kehati R, Erek CM, Bar-Oz G, Pompanon F, Cumer T, Çakırlar C, Mohaseb AF, Decruyenaere D, Davoudi H, Çevik Ö, Rollefson G, Vigne JD, Khazaeli R, Fathi H, Doost SB, Rahimi Sorkhani R, Vahdati AA, Sauer EW, Azizi Kharanaghi H, Maziar S, Gasparian B, Pinhasi R, Martin L, Orton D, Arbuckle BS, Benecke N, Manica A, Horwitz LK, Mashkour M, Bradley DG.

Science. 2018 Jul 6;361(6397):85-88. doi: 10.1126/science.aas9411.

PMID:
29976826
18.

Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia.

Davids MS, Hallek M, Wierda W, Roberts AW, Stilgenbauer S, Jones JA, Gerecitano JF, Kim SY, Potluri J, Busman T, Best A, Verdugo ME, Cerri E, Desai M, Hillmen P, Seymour JF.

Clin Cancer Res. 2018 Sep 15;24(18):4371-4379. doi: 10.1158/1078-0432.CCR-17-3761. Epub 2018 Jun 12.

19.

Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.

Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S, Jurczak W, Mulligan SP, Schuh A, Assouline S, Wendtner CM, Roberts AW, Davids MS, Bloehdorn J, Munir T, Böttcher S, Zhou L, Salem AH, Desai M, Chyla B, Arzt J, Kim SY, Verdugo M, Gordon G, Hallek M, Wierda WG.

J Clin Oncol. 2018 Jul 1;36(19):1973-1980. doi: 10.1200/JCO.2017.76.6840. Epub 2018 May 1. Erratum in: J Clin Oncol. 2019 Sep 1;37(25):2299.

PMID:
29715056
20.

Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies.

Place AE, Goldsmith K, Bourquin JP, Loh ML, Gore L, Morgenstern DA, Sanzgiri Y, Hoffman D, Zhou Y, Ross JA, Prine B, Shebley M, McNamee M, Farazi T, Kim SY, Verdugo M, Lash-Fleming L, Zwaan CM, Vormoor J.

Future Oncol. 2018 Sep;14(21):2115-2129. doi: 10.2217/fon-2018-0121. Epub 2018 Mar 29.

21.

A Holistic Theoretical Approach to Intellectual Disability: Going Beyond the Four Current Perspectives.

Schalock RL, Luckasson R, Tassé MJ, Verdugo MA.

Intellect Dev Disabil. 2018 Apr;56(2):79-89. doi: 10.1352/1934-9556-56.2.79.

PMID:
29584556
22.

Low-level orientation information for social evaluation in face images.

Balas B, Verdugo MQ.

Psychon Bull Rev. 2018 Dec;25(6):2224-2230. doi: 10.3758/s13423-018-1438-5.

PMID:
29404799
23.

Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy.

Coutre S, Choi M, Furman RR, Eradat H, Heffner L, Jones JA, Chyla B, Zhou L, Agarwal S, Waskiewicz T, Verdugo M, Humerickhouse RA, Potluri J, Wierda WG, Davids MS.

Blood. 2018 Apr 12;131(15):1704-1711. doi: 10.1182/blood-2017-06-788133. Epub 2018 Jan 5.

24.

Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.

Jones JA, Mato AR, Wierda WG, Davids MS, Choi M, Cheson BD, Furman RR, Lamanna N, Barr PM, Zhou L, Chyla B, Salem AH, Verdugo M, Humerickhouse RA, Potluri J, Coutre S, Woyach J, Byrd JC.

Lancet Oncol. 2018 Jan;19(1):65-75. doi: 10.1016/S1470-2045(17)30909-9. Epub 2017 Dec 12.

25.

Understanding organization transformation in evaluation and program planning.

Schalock RL, Verdugo MA, van Loon J.

Eval Program Plann. 2018 Apr;67:53-60. doi: 10.1016/j.evalprogplan.2017.11.003. Epub 2017 Nov 24.

PMID:
29197716
26.
27.

Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.

Kumar S, Kaufman JL, Gasparetto C, Mikhael J, Vij R, Pegourie B, Benboubker L, Facon T, Amiot M, Moreau P, Punnoose EA, Alzate S, Dunbar M, Xu T, Agarwal SK, Enschede SH, Leverson JD, Ross JA, Maciag PC, Verdugo M, Touzeau C.

Blood. 2017 Nov 30;130(22):2401-2409. doi: 10.1182/blood-2017-06-788786. Epub 2017 Oct 10.

PMID:
29018077
28.

Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM.

Moreau P, Chanan-Khan A, Roberts AW, Agarwal AB, Facon T, Kumar S, Touzeau C, Punnoose EA, Cordero J, Munasinghe W, Jia J, Salem AH, Freise KJ, Leverson JD, Enschede SH, Ross JA, Maciag PC, Verdugo M, Harrison SJ.

Blood. 2017 Nov 30;130(22):2392-2400. doi: 10.1182/blood-2017-06-788323. Epub 2017 Aug 28.

PMID:
28847998
29.

Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma.

Parikh A, Gopalakrishnan S, Freise KJ, Verdugo ME, Menon RM, Mensing S, Salem AH.

Leuk Lymphoma. 2018 Apr;59(4):871-879. doi: 10.1080/10428194.2017.1361024. Epub 2017 Aug 10.

PMID:
28797193
30.

Disability Policy Implementation From a Cross-Cultural Perspective.

Verdugo MA, Jenaro C, Calvo I, Navas P.

Intellect Dev Disabil. 2017 Jul;55(4):234-246. doi: 10.1352/1934-9556-55.4.234.

PMID:
28753399
31.

Moving Beyond Maximum Tolerated Dose for Targeted Oncology Drugs: Use of Clinical Utility Index to Optimize Venetoclax Dosage in Multiple Myeloma Patients.

Freise KJ, Jones AK, Verdugo ME, Menon RM, Maciag PC, Salem AH.

Clin Pharmacol Ther. 2017 Dec;102(6):970-976. doi: 10.1002/cpt.712. Epub 2017 May 26.

PMID:
28419431
32.

Evidence and Evidence-Based Practices: Are We There Yet?

Schalock RL, Gomez LE, Verdugo MA, Claes C.

Intellect Dev Disabil. 2017 Apr;55(2):112-119. doi: 10.1352/1934-9556-55.2.112.

PMID:
28375801
33.

Study of conformational changes and protein aggregation of bovine serum albumin in presence of Sb(III) and Sb(V).

Verdugo M, Ruiz Encinar J, Costa-Fernández JM, Menendez-Miranda M, Bouzas-Ramos D, Bravo M, Quiroz W.

PLoS One. 2017 Feb 2;12(2):e0170869. doi: 10.1371/journal.pone.0170869. eCollection 2017.

34.

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.

Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, Puvvada S, Kipps TJ, Anderson MA, Salem AH, Dunbar M, Zhu M, Peale F, Ross JA, Gressick L, Desai M, Kim SY, Verdugo M, Humerickhouse RA, Gordon GB, Gerecitano JF.

J Clin Oncol. 2017 Mar 10;35(8):826-833. doi: 10.1200/JCO.2016.70.4320. Epub 2017 Jan 17.

35.

Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.

Seymour JF, Ma S, Brander DM, Choi MY, Barrientos J, Davids MS, Anderson MA, Beaven AW, Rosen ST, Tam CS, Prine B, Agarwal SK, Munasinghe W, Zhu M, Lash LL, Desai M, Cerri E, Verdugo M, Kim SY, Humerickhouse RA, Gordon GB, Kipps TJ, Roberts AW.

Lancet Oncol. 2017 Feb;18(2):230-240. doi: 10.1016/S1470-2045(17)30012-8. Epub 2017 Jan 13.

36.

Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy.

Freise KJ, Jones AK, Menon RM, Verdugo ME, Humerickhouse RA, Awni WM, Salem AH.

Hematol Oncol. 2017 Dec;35(4):679-684. doi: 10.1002/hon.2373. Epub 2016 Dec 16.

PMID:
27982454
38.

Examining age-related differences in support needs on the Supports Intensity Scale-Children's Version-Spanish translation.

Verdugo MA, Arias B, Guillén VM, Seo H, Shogren KA, Shaw LA, Thompson JR.

Int J Clin Health Psychol. 2016 Sep-Dec;16(3):306-314. doi: 10.1016/j.ijchp.2016.06.002. Epub 2016 Jul 25.

39.

Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.

Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, Puvvada SD, Wendtner CM, Roberts AW, Jurczak W, Mulligan SP, Böttcher S, Mobasher M, Zhu M, Desai M, Chyla B, Verdugo M, Enschede SH, Cerri E, Humerickhouse R, Gordon G, Hallek M, Wierda WG.

Lancet Oncol. 2016 Jun;17(6):768-778. doi: 10.1016/S1470-2045(16)30019-5. Epub 2016 May 10.

PMID:
27178240
40.

A systematic approach to an organization's sustainability.

Schalock RL, Verdugo M, Lee T.

Eval Program Plann. 2016 Jun;56:56-63. doi: 10.1016/j.evalprogplan.2016.03.005. Epub 2016 Mar 19.

PMID:
27058776
41.

A new scale for the measurement of quality of life in children with intellectual disability.

Gómez LE, Alcedo MÁ, Arias B, Fontanil Y, Arias VB, Monsalve A, Verdugo MÁ.

Res Dev Disabil. 2016 Jun-Jul;53-54:399-410. doi: 10.1016/j.ridd.2016.03.005. Epub 2016 Mar 21.

PMID:
27010958
42.

p38γ and p38δ reprogram liver metabolism by modulating neutrophil infiltration.

González-Terán B, Matesanz N, Nikolic I, Verdugo MA, Sreeramkumar V, Hernández-Cosido L, Mora A, Crainiciuc G, Sáiz ML, Bernardo E, Leiva-Vega L, Rodríguez E, Bondía V, Torres JL, Perez-Sieira S, Ortega L, Cuenda A, Sanchez-Madrid F, Nogueiras R, Hidalgo A, Marcos M, Sabio G.

EMBO J. 2016 Mar 1;35(5):536-52. doi: 10.15252/embj.201591857. Epub 2016 Feb 3.

43.

Do environmental barriers affect the parent-reported quality of life of children and adolescents with cerebral palsy?

Badia M, Begoña Orgaz M, Gómez-Vela M, Verdugo MA, Ullán AM, Longo E.

Res Dev Disabil. 2016 Feb-Mar;49-50:312-21. doi: 10.1016/j.ridd.2015.12.011. Epub 2016 Jan 11.

PMID:
26788697
44.

Confirmatory factor analysis of the supports intensity scale for children.

Verdugo MA, Guillén VM, Arias B, Vicente E, Badia M.

Res Dev Disabil. 2016 Feb-Mar;49-50:140-52. doi: 10.1016/j.ridd.2015.11.022. Epub 2015 Dec 17.

PMID:
26707926
45.

Moving Us Toward a Theory of Individual Quality of Life.

Schalock RL, Verdugo MA, Gomez LE, Reinders HS.

Am J Intellect Dev Disabil. 2016 Jan;121(1):1-12. doi: 10.1352/1944-7558-121.1.1.

PMID:
26701070
46.

[Biological maturation process and athletic performance].

Verdugo MF.

Rev Chil Pediatr. 2015 Nov-Dec;86(6):383-5. doi: 10.1016/j.rchipe.2015.10.003. Spanish. No abstract available.

47.

Perisciatic Ultrasound-Guided Infiltration for Treatment of Deep Gluteal Syndrome: Description of Technique and Preliminary Results.

Rosales J, García N, Rafols C, Pérez M, Verdugo MA.

J Ultrasound Med. 2015 Nov;34(11):2093-7. doi: 10.7863/ultra.14.12030. Epub 2015 Oct 7.

PMID:
26446817
48.

[Early neonatal sepsis, incidence and associated risk factors in a public hospital in western Mexico].

Pérez RO, Lona JC, Quiles M, Verdugo MÁ, Ascencio EP, Benítez EA.

Rev Chilena Infectol. 2015 Aug;32(4):387-92. doi: 10.4067/S0716-10182015000500003. Spanish.

49.

Operationalisation of quality of life for adults with severe disabilities.

Gómez LE, Arias B, Verdugo MÁ, Tassé MJ, Brown I.

J Intellect Disabil Res. 2015 Oct;59(10):925-41. doi: 10.1111/jir.12204. Epub 2015 May 27.

PMID:
26018763
50.

A psychometric evaluation of the ARC-INICO Self-Determination Scale for adolescents with intellectual disabilities.

Verdugo MA, Vicente E, Fernández-Pulido R, Gómez-Vela M, Wehmeyer ML, Guillén VM.

Int J Clin Health Psychol. 2015 May-Aug;15(2):149-159. doi: 10.1016/j.ijchp.2015.03.001. Epub 2015 Apr 14.

Supplemental Content

Loading ...
Support Center